# M.D. Anderson Cancer Center: Phase 1 study completed, 18 enrolled (Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | M.D. Anderson Cancer Center |
| Sponsor type | Academic and hospital |
| Study | Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT |
| NCT ID | NCT03435952 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites |
| Intervention types | drug, biological |
| Target enrollment | 18 |
| Site countries | United States |
| Posted | 2018-02-19 |
| Planned start | 2018-07-10 |
| Event | Completed |
| Event date | 2026-10-30 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03435952). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.